Elypta

About:

Preventing cancer mortality by developing a metabolism-based liquid biopsy platform for early detection and monitoring

Website: https://www.elypta.com/

Twitter/X: ElyptaDx

Top Investors: Chalmers Ventures AB, Norrsken VC, Sciety, EASME - EU Executive Agency for SMEs, Nina Capital

Description:

Elypta is developing a metabolism-based liquid biopsy platform based on a new IVD laboratory assay kit and artificial intelligence algorithms trained by their clinical database. Elypta proudly sponsors the clinical trial series AURORAX to investigate applications in their lead indication renal cell carcinoma from surveillance of recurrence to monitoring treatment response. They also explore several other indications to understand the full potential for Elypta’s platform.